Blockchain Registration Transaction Record

Lexaria Bioscience Begins GLP-1 Study, Files New Patents

Lexaria Bioscience announces start of Animal Study #1 evaluating DehydraTECH-GLP-1 and CBD formulations, files three new patents for SNAC alternatives, and receives Australian patent for hypertension treatments.

Lexaria Bioscience Begins GLP-1 Study, Files New Patents

This news matters because Lexaria's exploration of SNAC alternatives could disrupt the GLP-1 drug market, which includes blockbusters like Rybelsus and Wegovy. If successful, DehydraTECH formulations may offer improved brain biodistribution, potentially enhancing efficacy and reducing side effects for diabetes and obesity treatments. The new patent on hypertension therapies also broadens Lexaria's pipeline, impacting patients seeking more effective oral drug delivery options.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xe6fb2b0a181c0e8fbc611a2671fb1ca6ac16c2c29d4cc84f9ef74cb28f2c1e6a
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintovalLgo7-8464d7d47c05346ea5e9db8f1c18cd0f